A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum

Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.

Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.

Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.

Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.